Gateway to Explore Product Innovation in the GLP-1 Era at SupplySide Global
Fairfield, CA – October 15, 2026 – Gateway Health Alliances President Shil Kothari and Product Development Manager Avi Kothari will share insights on product innovation in the GLP-1 era during separate panels at SupplySide Global, October 26–30, at Mandalay Bay in Las Vegas.
The sessions will explore opportunities for brands and formulators to use clinically supported ingredients to address evolving consumer needs in weight management and metabolic health.
Sessions:
§ GLP-1 Breakout Session: Supporting consumers as they stop using GLP-1s
Panel participant: Shil Kothari, president
Monday, October 26, 4:45–5:30 p.m.
South Pacific Ballroom F, Lower Level
The discussion will examine nutritional needs and product opportunities for consumers transitioning off GLP-1 medications, including appetite and satiety support, muscle maintenance, and broader metabolic health. Kothari will also address clinical evidence, research gaps, and considerations for responsible product positioning.
§ How GLP-1s are driving innovation across product categories Panel participant: Avi Kothari, product development manager
Wednesday, October 28, 11:30 a.m.–12:30 p.m.
Innovation Stage, Booth #4815, Bayside D, Level 1
This panel will explore the science and market trends shaping innovation in the GLP-1 era, with companies sharing ingredient solutions and product development strategies for weight management and metabolic health.
Full schedule: supplysideglobal.com
“GLP-1s are changing how consumers think about weight management and what they expect from nutrition products,” said Shil Kothari, president of Gateway Health Alliances. “Brands and formulators have an opportunity to develop multifunctional products that support appetite and satiety alongside the metabolic systems connected to healthy weight. Clinically validated botanicals give us a foundation for meaningful innovation, with benefits that extend beyond pounds lost.”
Gateway’s research includes a 16-week randomized, double-blind, placebo-controlled study evaluating Dyglomera®, a patented extract of Dichrostachys glomerata, and CQR-300®, a patented extract of Cissus quadrangularis. Published in the peer-reviewed journal Medicina, the study found that both ingredients increased the body’s natural GLP-1 response and reduced activity of DPP-4, the enzyme that breaks down GLP-1.
These findings complement Gateway’s broader research into botanical support for leptin, adiponectin and insulin-related pathways. Together, these interconnected systems help regulate appetite, glucose handling and energy balance, making them essential considerations for long-term weight management and metabolic health.
